secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001790340-23-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q1 net loss $13.6M; positive Phase 1 data for IMM-1-104 accelerates timeline
--------------------------------------------------------------------------------

- Net loss $13.6M ($0.51/sh) for Q1 2023; cash & equivalents $91.5M as of Mar 31, 2023.
- Positive initial Phase 1 PK, PD, safety data for IMM-1-104: significant PK Cmax, ~2h half-life, no DLTs.
- RP2D expected early 2024 (accelerated); potential to assess preliminary efficacy sooner than anticipated.
- Completed $30M stock offering (2.73M shares at $11.00); cash runway extended into 2025.
- Appointed Harold E. Brakewood as CBO in March 2023; IND for IMM-6-415 expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034023000022/0001790340-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034023000022/imrx-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001790340-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer